Progressive loss of β-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes

Diabetes Care

Volumn 30, Issue 3, 2007, Pages 677-682

  Cnop, Miriam ^a,e   Vidal, Josep ^a,f   Hull, Rebecca L ^a   Utzschneider, Kristina M ^a   Carr, Darcy B ^b   Schraw, Todd ^c   Scherer, Philipp E ^c   Boyko, Edward J ^a   Fujimoto, Wilfred Y ^a   Kahn, Steven E ^a,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^e ERASME HOSPITAL   (Belgium)

^f HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; TOLBUTAMIDE;

ADULT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; RELATIVE; RISK ASSESSMENT; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADIPONECTIN; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; BODY SIZE; DIABETES MELLITUS, TYPE 2; FAMILY; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MIDDLE AGED; PREDIABETIC STATE; RISK FACTORS; SENSITIVITY AND SPECIFICITY; WEIGHT GAIN;

EID: 33847636157     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-1834     Document Type: Article

References (33)

1. Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, Freymond D, Nyomba BL, Zurlo F, Swinburn B, Bogardus C: Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318:1217-1225, 1988
2. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR: Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 113:909-915, 1990
3. Kahn SE: The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3-19, 2003
4. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, et al.: Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663-1672, 1993
5. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, Dailey G, Gerich J: Pancreatic β-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 273:1855-1861, 1995
6. van Haeften TW, Dubbeldam S, Zonderland ML, Erkelens DW: Insulin secretion in normal glucose-tolerant relatives of type 2 diabetic subjects: assessments using hyperglycemic glucose clamps and oral glucose tolerance tests. Diabetes Care 21:278-282, 1998
7. Larsson H, Ahren B: Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. Diabetologia 39:1099-1107, 1996
8. Ward WK, Johnston CLW, Beard JC, Benedetti TJ, Halter JB, Porte D Jr: Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes 34:861-869, 1985
9. Dunaif A, Finegood DT: β-Cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:942-947, 1996
10. Best JD, Kahn SE, Ader M, Watanabe RM, Ni TC, Bergman RN: Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care 19:1018-1030, 1996
11. Welch S, Gebhart SS, Bergman RN, Phillips LS: Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 71:1508-1518, 1990
12. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR: Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340:925-929, 1992
13. Kahn SE, Klaff LJ, Schwartz MW, Beard JC, Bergman RN, Taborsky GJ Jr, Porte D Jr: Treatment with a somatostatin analog decreases pancreatic β-cell and whole body sensitivity to glucose. J Clin Endocrinol Metab 71:994-1002, 1990
14. Raffel LJ, Robbins DC, Norris JM, Boerwinkle E, DeFronzo RA, Elbein SC, Fujimoto W, Hanis CL, Kahn SE, Permutt MA, Chiu KC, Cruz J, Ehrmann DA, Robertson RP, Rotter JI, Buse J: The GENNID Study: a resource for mapping the genes that cause NIDDM. Diabetes Care 19:864-872, 1996
15. American Diabetes Association: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183-1197, 1997
16. Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, Hawkins M: Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53:1621-1629, 2004
17. Utzschneider KM, Prigeon RL, Carr DB, Hull RL, Tong J, Shofer JB, Retzlaff BM, Knopp RH, Kahn SE: Impact of differences in fasting glucose and glucose tolerance on the hyperbolic relationship between insulin sensitivity and insulin responses. Diabetes Care 29:356-362, 2006
18. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE: β-Cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 51:2170-2178, 2002
19. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999
20. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS: Insulin secretory defects in polycystic ovary syndrome: relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 96:520-527, 1995
21. Larsson H, Ahren B: Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women. Diabetologia 43:194-202, 2000
22. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC: UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years: UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 15:297-303, 1998
23. Festa A, Williams K, D'Agostino R Jr, Wagenknecht LE, Haffner SM: The natural course of β-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 55:1114-1120, 2006
24. Xiang AH, Wang C, Peters RK, Trigo E, Kjos SL, Buchanan TA: Coordinate changes in plasma glucose and pancreatic β-cell function in Latino women at high risk for type 2 diabetes. Diabetes 55:1074-1079, 2006
25. Kriketos AD, Carey DG, Jenkins AB, Chisholm DJ, Furler SM, Campbell LV: Central fat predicts deterioration of insulin secretion index and fasting glycaemia: 6-year follow-up of subjects at varying risk of type 2 diabetes mellitus. Diabet Med 20:294-300, 2003
26. Bonora E, Zavaroni I, Coscelli C, Butturini U: Decreased hepatic insulin extraction in subjects with mild glucose intolerance. Metabolism 32:438-446, 1983
27. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
28. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
29. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803, 2002
30. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
31. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096-1105, 2006
32. Utzschneider KM, Carr DB, Barsness SM, Kahn SE, Schwartz RS: Diet-induced weight loss is associated with an improvement in β-cell function in older men. J Clin Endocrinol Metab 89:2704-2710, 2004
33. Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, Murphy MB, Shamoon H: Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 54:2404-2414, 2005